Introduction to Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma

Murphy, Michael J.

doi:10.1007/978-1-60761-433-3_1

Cited by 5 publications

(7 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CSCs differ from the adult stem cells in that their division results in tumor initiation and growth [ 26 ]. Recently, it has been suggested that melanomas may be derived from transformed melanocytic stem cells, melanocyte progenitors, or de-differentiated mature melanocytes [ 27 ].…”

Section: Introductionmentioning

confidence: 99%

“…There are several key stem cells markers specified for malignant melanoma: CD20, CD133, ABCB5, CD271 and ALDH1A [ 28 ]. Recently identified melanoma stem cell markers include JARID1B (jumonji, AT-rich interactive domain 1B), ABCB5 (ATP-binding cassette subfamily B (MDR/TAP) member 5), ABCG2 (ATP-binding cassette subfamily G member 2), and MDR1 (multi-drug resistance 1) [ 27 ]. These JARID1B-positive melanoma cells gave rise to a highly proliferative progeny, and knockdown of JARID1B led to accelerated tumor growth, which was followed by exhaustion.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma

Demkova

Kučerová

2018

Mol Cancer

View full text Add to dashboard Cite

Metastatic disease in a cancer patient still remains a therapeutic challenge. Metastatic process involves many steps, during which malignant cells succeed to activate cellular pathways promoting survival in hostile environment, engraftment and growth at the distant site from the primary tumor. Melanoma is known for its high propensity to produce metastases even at the early stages of the disease. Here we summarize the most important molecular mechanisms which were associated with the melanoma metastasis. Then, we specifically focus on the signaling pathway mediated by hepatocyte growth factor (HGF) and its receptor c-Met, which play an important role during physiological processes and were been associated with tumorigenesis. We also focus on the effect of the small molecule inhibitors of the tyrosine kinase domain of the c-Met receptor and its effects on properties of melanoma cell. We summarize recent studies, which involved inhibition of the HGF/c-Met signaling in order to decrease melanoma growth and metastatic capacity.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma

Demkova

Kučerová

2018

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…Recent advancements in molecular technologies have yielded a wide array of genetic, epigenetic, and protein biomarkers as prognostic and predictive markers in the management of melanoma patients [1, 2]. Multiple bio-markers have been found to be associated in melanoma progression, proliferation, immune response, oncogenesis, and others from the tissue microarray studies [2].…”

Section: Introductionmentioning

confidence: 99%

Progression of cutaneous melanoma: implications for treatment

Leong

Mihm

Murphy

et al. 2012

Clin Exp Metastasis

View full text Add to dashboard Cite

The survival rates of melanoma, like any type of cancer, become worse with advancing stage. Spectrum theory is most consistent with the progression of melanoma from the primary site to the in-transit locations, regional or sentinel lymph nodes and beyond to the distant sites. Therefore, early diagnosis and surgical treatment before its spread is the most effective treatment. Recently, new approaches have revolutionized the diagnosis and treatment of melanoma. Genomic profiling and sequencing will form the basis for molecular taxonomy for more accurate subgrouping of melanoma patients in the future. New insights of molecular mechanisms of metastasis are summarized in this review article. Sentinel lymph node biopsy has become a standard of care for staging primary melanoma without the need for a more morbid complete regional lymph node dissection. With recent developments in molecular biology and genomics, novel molecular targeted therapy is being developed through clinical trials.

show abstract

“…It is however important to note that many were reactive against transcription factors, tumour suppressors and promoters, markers of apoptosis, and regulators of pigmentation and T-cell differentiation that may influence an array of cancer-related pathways. Some of the top 139 seroreactive antigens such as VEGFb, p53, MITF, KIT and MLANA [ 22 ] have previously been associated with melanoma and cancer in general, indicating that the detected autoantibody response may be derived from an antitumour response.…”

Section: Resultsmentioning

confidence: 99%

A diagnostic autoantibody signature for primary cutaneous melanoma

Zaenker

Pearce

et al. 2018

Oncotarget

View full text Add to dashboard Cite

Melanoma is an aggressive form of skin cancer that is curable by surgical excision in the majority of cases, if detected at an early stage. To improve early stage melanoma detection, the development of a highly sensitive diagnostic test is of utmost importance. Here we aimed to identify antibodies to a panel of tumour associated antigens that can differentiate primary melanoma patients and healthy individuals. A total of 245 sera from primary melanoma patients and healthy volunteers were screened against a high-throughput microarray platform containing 1627 functional proteins. Following rigorous statistical analysis, we identified a combination of 10 autoantibody biomarkers that, as a panel, displays a sensitivity of 79%, specificity of 84% and an AUC of 0.828 for primary melanoma detection. This melanoma autoantibody signature may prove valuable for the development of a diagnostic blood test for routine population screening that, when used in conjunction with current melanoma diagnostic techniques, could improve the early diagnosis of this malignancy and ultimately decrease the mortality rate of patients.

show abstract

Introduction to Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma

Cited by 5 publications

References 7 publications

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma

Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma

Progression of cutaneous melanoma: implications for treatment

A diagnostic autoantibody signature for primary cutaneous melanoma

Contact Info

Product

Resources

About